Veeva Systems (NYSE:VEEV) Releases FY 2025 Earnings Guidance

Veeva Systems (NYSE:VEEV) updated its FY 2025 earnings guidance on Wednesday. The company provided EPS guidance of 6.220-6.220 for the period, compared to the consensus EPS estimate of 6.160. The company issued revenue guidance of $2.7 billion-$2.7 billion, compared to the consensus revenue estimate of $2.7 billion. Veeva Systems also updated its FY25 guidance to $6.22 EPS.

Veeva Systems Stock Down 0.3 %

Shares of NYSE VEEV opened at $216.47 on Friday. Veeva Systems has a twelve month low of $162.72 and a twelve month high of $236.90. The firm has a market cap of $34.99 billion, a P/E ratio of 63.86, a PEG ratio of 1.95 and a beta of 0.80. The company has a 50 day moving average of $188.49 and a 200 day moving average of $202.13.

Veeva Systems (NYSE:VEEV) last issued its quarterly earnings data on Thursday, May 30th. The technology company reported $1.03 earnings per share for the quarter, beating analysts’ consensus estimates of $0.93 by $0.10. Veeva Systems had a net margin of 22.34% and a return on equity of 12.74%. The company had revenue of $650.35 million for the quarter, compared to the consensus estimate of $641.73 million. As a group, equities analysts expect that Veeva Systems will post 4.19 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts have weighed in on VEEV shares. Guggenheim increased their price target on shares of Veeva Systems from $211.00 to $233.00 and gave the stock a buy rating in a research report on Thursday, July 18th. Evercore ISI reduced their price target on Veeva Systems from $230.00 to $200.00 and set an in-line rating for the company in a research report on Friday, May 31st. TD Cowen boosted their price objective on Veeva Systems from $180.00 to $192.00 and gave the company a hold rating in a research note on Thursday. Robert W. Baird lifted their price target on shares of Veeva Systems from $245.00 to $251.00 and gave the company an outperform rating in a report on Thursday. Finally, Piper Sandler raised their price objective on shares of Veeva Systems from $225.00 to $230.00 and gave the company an overweight rating in a research report on Thursday. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and sixteen have given a buy rating to the company. According to data from MarketBeat, Veeva Systems presently has a consensus rating of Moderate Buy and an average price target of $230.13.

Insider Activity

In other news, CFO Timothy S. Cabral sold 15,000 shares of the company’s stock in a transaction that occurred on Friday, June 7th. The shares were sold at an average price of $184.33, for a total value of $2,764,950.00. Following the completion of the sale, the chief financial officer now owns 8,391 shares of the company’s stock, valued at approximately $1,546,713.03. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, CFO Timothy S. Cabral sold 15,000 shares of the business’s stock in a transaction on Friday, June 7th. The stock was sold at an average price of $184.33, for a total value of $2,764,950.00. Following the completion of the transaction, the chief financial officer now directly owns 8,391 shares of the company’s stock, valued at approximately $1,546,713.03. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, SVP Jonathan Faddis sold 2,353 shares of the firm’s stock in a transaction dated Wednesday, August 21st. The shares were sold at an average price of $200.00, for a total value of $470,600.00. Following the sale, the senior vice president now directly owns 9,035 shares in the company, valued at approximately $1,807,000. The disclosure for this sale can be found here. Insiders own 10.50% of the company’s stock.

About Veeva Systems

Veeva Systems Inc provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States.